---
title: "EMA Panel Recommends Bayer’s Finerenone for Heart Failure with Preserved Ejection Fraction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274308829.md"
datetime: "2026-01-30T12:26:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274308829.md)
  - [en](https://longbridge.com/en/news/274308829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274308829.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274308829.md) | [繁體中文](https://longbridge.com/zh-HK/news/274308829.md)


# EMA Panel Recommends Bayer’s Finerenone for Heart Failure with Preserved Ejection Fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Bayer AG’s finerenone (Kerendia™) for the treatment of adults with heart failure with left ventricular ejection fraction (LVEF) ≥40%, which includes those with mildly reduced or preserved ejection fraction. The recommendation is based on results from the Phase III FINEARTS-HF study, which demonstrated that finerenone significantly reduced the composite endpoint of cardiovascular death and total heart failure events compared to placebo in addition to standard therapy. The final decision from the European Commission is expected in the coming weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on January 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Bayer AG (BAYN.DE)](https://longbridge.com/en/quote/BAYN.DE.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Bayer Aktiengesellschaft (BAYRY.US)](https://longbridge.com/en/quote/BAYRY.US.md)

## Related News & Research

- [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/en/news/280969658.md)
- [UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer](https://longbridge.com/en/news/281501722.md)
- [Bayer - AskBio announces completion of enrollment in phase 2 clinical trial of AB-1002](https://longbridge.com/en/news/281314240.md)
- [Bayer Reaffirms Pharma Targets, Aiming for 30% Margin](https://longbridge.com/en/news/281359378.md)
- [Bayer rejigs marketing claims after advertising body challenge](https://longbridge.com/en/news/281525890.md)